A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

What Was Tested

In this phase 2 trial, researchers set out to test Tirzepatide and Bimagrumab.

The study will last about 70 weeks.

It had 12 arms (groups): one (experimental), one (active comparator), one (active comparator), one (experimental) and one (experimental).

Participants will receive bimagrumab subcutaneously (SC) and tirzepatide placebo SC.

Participants will receive bimagrumab placebo SC and tirzepatide SC.

Participants will receive bimagrumab placebo SC and tirzepatide SC.

The registry classes the interventions as drug.

Who Took Part

The registry lists 252 actual participants took part.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a BMI of. ≥30 kilograms per square meter (kg/m2) or. ≥27 kg/m2 and \<30 kg/m2, with at least one of the following weight-related comorbidities:. Obstructive sleep apnea.

The full record lists 8 inclusion and 19 exclusion criteria; among the exclusions: have a prior or planned surgical treatment for obesity; use of metformin, or any other glucose-lowering medications; have poorly controlled hypertension.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

The Tirzepatide group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Tirzepatide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2024-10-21 with completion listed for 2026-01-16.

It ran at 12 sites in United States (12).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Percent Change from Baseline in Body Weight (time frame: Baseline, Week 24).

It also tracked 10 secondary outcomes, for example Percent Change from Baseline in Total Body Fat Mass by Dual-Energy X-Ray Absorptiometry (DXA), Change from Baseline in Body Weight, Change from Baseline in Waist Circumference, Change from Baseline in Body Mass Index (BMI), Change from Baseline in Waist-to-Height Ratio (WHtR) and Percent Change from Baseline in Visceral Adipose Tissue (VAT).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Tirzepatide and Bimagrumab in 252 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Bimagrumab compound page, all human trials.